Psychedelics & Bipolar Disorder: Psilocybin, Ketamine & Science | Dr. Josh Woolley |

Psychiatrist and psychedelics researcher Dr. Josh Woolley (University of California San Francisco), and peer researcher Amir speak on psilocybin, ketamine, and psychedelics and their links with bipolar disorder, and what the science says about psychedelics as treatment. Hosted by Dr. Erin Michalak.
#talkBD Bipolar Disorder Podcast
talkBD gathers researchers, people with lived experience, healthcare providers, and top bipolar disorder experts from around the world to discuss and answer the most important questions about living with bipolar disorder. Our episodes are available on all podcast platforms:
Spotify: open.spotify.c...
Apple: podcasts.apple...
Google: podcasts.googl...
Learn more about talkBD: talkBD.live
Dr. Josh Woolley is currently the principal investigator and director of UCSF’s Bonding and Attunement in Neuropsychiatric Disorders (BAND) Laboratory. The lab’s mission is to understand mechanisms of social connection among individuals with mental illness and to test new treatments. The BAND Lab studies psychedelics as novel therapeutics for multiple conditions, including bipolar disorder. He’s also the director of the translational psychedelic research program at UCSF.
Amir is a recent graduate of UBC in a bachelors of science in cognitive systems where he focused on cognition and the brain. He is a peer researcher at CREST.BD and is starting his role as a peer mental health support worker at Foundry. As an individual with lived experience, he has been a researcher on UBC and UCSF’s joint project on investigating the use of Psilocybin in individuals with bipolar disorder.